fashion -WSS

fashion

author：entertainment 2025-10-01 20:14:57 - browse：734

Blue numbers and letter falling down a tunnel. -- health tech coverage from STAT — Adobe

A growing number of AI tools are being used to predict everything from sepsis to strokes, with the hope of accelerating the delivery of life-saving care. But over time, new research suggests, these predictive models can become a victim of their own success — sending their performance into a nosedive and generating inaccurate, potentially harmful results.

“There is no accounting for this when your models are being tested,” said Akhil Vaid, an instructor of data-driven and digital medicine at the Icahn School of Medicine at Mount Sinai and author of the new research, published Monday in the Annals of Internal Medicine. “You can’t run validation studies, do external validation, run clinical trials — because all they’ll tell you is that the model works. And when it starts to work, that is when the problems will arise.”

Vaid and his Mount Sinai colleagues simulated the deployment of two models that predicted a patient’s risk of dying and acute kidney injury within five days of entering the ICU. Their simulations assumed that the models did what they were supposed to — lower deaths and kidney injury by identifying patients for earlier intervention.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： What to make of Biden’s latest efforts on cancer research

WSS

Tocagen's brain cancer gene therapy trial continues. Investors worry

Judge rejects Trump's request to move Stormy Daniels hush

Hospitals consider fixing cancer drug shortages on their own

I learned firsthand about improving diversity in clinical trials

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

knowledge

fashion

explore

Walensky prepares to leave CDC — and Congress — behind

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Supreme Court strikes down use of affirmative action

Generate Biomedicines machine learning biotech raises $273M

Psychedelics group wrestles with new pharma identity

Tocagen's brain cancer gene therapy trial continues. Investors worry

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Tesla recalling nearly 16,000 of its 2021

Medical records are filled with copy

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

entertainment

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Food makers to regulators: Ultra

Vir antibody drug aimed at influenza A fails in clinical trial

Food makers to regulators: Ultra

New Covid vaccine is recommended for everyone 6 months or older

Popular nasal decongestant doesn't actually relieve congestion

focus

knowledge

knowledge

hotspot